Business Wire

Elixir Medical Completes Enrollment in BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled ...
Yahoo Finance

Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion ...

Washington D.C. – October 28, 2024 – Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced late-breaking data demonstrating significant benefit of the ...
Business Wire

Elixir Medical Announces Outstanding 12-Month Data for DynamX Coronary Bioadaptor System, Demonstrating No Target Vessel Revascularization, No Thrombosis and Positive Adaptive ...

PARIS--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced outstanding 12-month data for the DynamX™ Coronary Bioadaptor System, the first ...
manilatimes

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard ...

DynamX® bioadaptor is the first interventional technology to demonstrate significant benefit with a reduction in long term adverse events in two consecutive randomized controlled trials MILPITAS, ...
Mena FN

Late-Breaking Data Demonstrate Significant Clinical Advantage of Elixir Medical’s DynamX Bioadaptor Over Standard of Care Drug-Eluting Stent at Two Years

(MENAFN- Iris Media Press Services) Dubai, UAE; May 17, 2024 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, announced two-year results ...
BioWorld

Elixir study shows that Dynamx is not inferior to Resolute Onyx

Elixir Medical Corp. reported that the Bioadaptor randomized controlled trial which compared its Dynamx coronary drug-eluting bioadaptor system to Dublin-based Medtronic plc’s Resolute Onyx ...
manilatimes

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical's DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- -Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX ® compared to DES- -Significantly lower ...
eturbonews

Elixir Medical’s 24-Month Clinical Results for DynamX Bioadaptor Showed Strong Safety Profile, With No Clinical Events

The DynamX Bioadaptor is a new class of treatment for Coronary Artery Disease. SINGAPORE, January 28, 2021 /EINPresswire.com/ — Elixir Medical’s 24-Month Clinical ...
Mena FN

Elixir Medical Announces Significant Late Breaking Clinical Results For Dynamx® Bioadaptor Demonstrating Nearly 50% Reduction In Coronary Event Rates Vs. Current PCI Standard ...

(MENAFN- GlobeNewsWire - Nasdaq) Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor is the first ...